Yale researchers have developed a machine learning model, called Immunostruct, that can help scientists create more personalized vaccines, including vaccines for cancer. They described the tool in Nature Machine Intelligence along with findings from applying it to cancer and immunology data.

    When a potential threat, such as a virus or tumor, arises in our body, our immune cells recognize peptides---essentially short proteins---on the surface of the invader and mount a defensive response. This small region that the immune system interacts with is known as an epitope. 

    Epitope-based vaccines are an emerging technology that contain specific peptides in order to trigger immune responses that precisely target particular diseases. Ongoing studies show that these vaccines are a promising potential immunotherapy for a range of cancers including melanomas, breast cancers, and glioblastomas. Researchers are also investigating whether these vaccines could more effectively combat new variants of infectious diseases.

    To develop these vaccines, scientists can use models that help them predict which peptides are most likely to trigger a strong immune response to a particular antigen. A limitation of many of these models, the researchers say, is that they treat peptides as a one-dimensional sequence of amino acids, not the three-dimensional, active structures that they are.

    Now, Yale researchers have created a model that also incorporates structural and biochemical properties of peptides. In the new study, they show that the multimodal model is more effective at identifying peptide candidates than its predecessors.

    "Cancer is extremely heterogeneous---which often makes it very hard to treat effectively," says Kevin B. Givechian, PhD, an MD-PhD student at Yale and co-first author on the study. “We have built a deep-learning model that integrates more information than had previously been combined to help us improve the identification of vaccine targets that stimulate people's immune system against their own tumor. Doing so would enable a more effective and less toxic method of treatment."

ВACKMAN, Isabella. Using Machine Learning to Develop Personalized Vaccines for Cancer. Yale School of Medicine, 24 fev. 2026. Acesso em: 28 june. 2026.

Yale researchers have developed a machine learning model, called Immunostruct, that can help scientists create more personalized vaccines, including vaccines for cancer. They described the tool in Nature Machine Intelligence along with findings from applying it to cancer and immunology data.

    When a potential threat, such as a virus or tumor, arises in our body, our immune cells recognize peptides---essentially short proteins---on the surface of the invader and mount a defensive response. This small region that the immune system interacts with is known as an epitope. 

    Epitope-based vaccines are an emerging technology that contain specific peptides in order to trigger immune responses that precisely target particular diseases. Ongoing studies show that these vaccines are a promising potential immunotherapy for a range of cancers including melanomas, breast cancers, and glioblastomas. Researchers are also investigating whether these vaccines could more effectively combat new variants of infectious diseases.

    To develop these vaccines, scientists can use models that help them predict which peptides are most likely to trigger a strong immune response to a particular antigen. A limitation of many of these models, the researchers say, is that they treat peptides as a one-dimensional sequence of amino acids, not the three-dimensional, active structures that they are.

    Now, Yale researchers have created a model that also incorporates structural and biochemical properties of peptides. In the new study, they show that the multimodal model is more effective at identifying peptide candidates than its predecessors.

    "Cancer is extremely heterogeneous---which often makes it very hard to treat effectively," says Kevin B. Givechian, PhD, an MD-PhD student at Yale and co-first author on the study. “We have built a deep-learning model that integrates more information than had previously been combined to help us improve the identification of vaccine targets that stimulate people's immune system against their own tumor. Doing so would enable a more effective and less toxic method of treatment."

ВACKMAN, Isabella. Using Machine Learning to Develop Personalized Vaccines for Cancer. Yale School of Medicine, 24 fev. 2026. Acesso em: 28 june. 2026.

Yale researchers have developed a machine learning model, called Immunostruct, that can help scientists create more personalized vaccines, including vaccines for cancer. They described the tool in Nature Machine Intelligence along with findings from applying it to cancer and immunology data.

    When a potential threat, such as a virus or tumor, arises in our body, our immune cells recognize peptides---essentially short proteins---on the surface of the invader and mount a defensive response. This small region that the immune system interacts with is known as an epitope. 

    Epitope-based vaccines are an emerging technology that contain specific peptides in order to trigger immune responses that precisely target particular diseases. Ongoing studies show that these vaccines are a promising potential immunotherapy for a range of cancers including melanomas, breast cancers, and glioblastomas. Researchers are also investigating whether these vaccines could more effectively combat new variants of infectious diseases.

    To develop these vaccines, scientists can use models that help them predict which peptides are most likely to trigger a strong immune response to a particular antigen. A limitation of many of these models, the researchers say, is that they treat peptides as a one-dimensional sequence of amino acids, not the three-dimensional, active structures that they are.

    Now, Yale researchers have created a model that also incorporates structural and biochemical properties of peptides. In the new study, they show that the multimodal model is more effective at identifying peptide candidates than its predecessors.

    "Cancer is extremely heterogeneous---which often makes it very hard to treat effectively," says Kevin B. Givechian, PhD, an MD-PhD student at Yale and co-first author on the study. “We have built a deep-learning model that integrates more information than had previously been combined to help us improve the identification of vaccine targets that stimulate people's immune system against their own tumor. Doing so would enable a more effective and less toxic method of treatment."

ВACKMAN, Isabella. Using Machine Learning to Develop Personalized Vaccines for Cancer. Yale School of Medicine, 24 fev. 2026. Acesso em: 28 june. 2026.

Yale researchers have developed a machine learning model, called Immunostruct, that can help scientists create more personalized vaccines, including vaccines for cancer. They described the tool in Nature Machine Intelligence along with findings from applying it to cancer and immunology data.

    When a potential threat, such as a virus or tumor, arises in our body, our immune cells recognize peptides---essentially short proteins---on the surface of the invader and mount a defensive response. This small region that the immune system interacts with is known as an epitope. 

    Epitope-based vaccines are an emerging technology that contain specific peptides in order to trigger immune responses that precisely target particular diseases. Ongoing studies show that these vaccines are a promising potential immunotherapy for a range of cancers including melanomas, breast cancers, and glioblastomas. Researchers are also investigating whether these vaccines could more effectively combat new variants of infectious diseases.

    To develop these vaccines, scientists can use models that help them predict which peptides are most likely to trigger a strong immune response to a particular antigen. A limitation of many of these models, the researchers say, is that they treat peptides as a one-dimensional sequence of amino acids, not the three-dimensional, active structures that they are.

    Now, Yale researchers have created a model that also incorporates structural and biochemical properties of peptides. In the new study, they show that the multimodal model is more effective at identifying peptide candidates than its predecessors.

    "Cancer is extremely heterogeneous---which often makes it very hard to treat effectively," says Kevin B. Givechian, PhD, an MD-PhD student at Yale and co-first author on the study. “We have built a deep-learning model that integrates more information than had previously been combined to help us improve the identification of vaccine targets that stimulate people's immune system against their own tumor. Doing so would enable a more effective and less toxic method of treatment."

ВACKMAN, Isabella. Using Machine Learning to Develop Personalized Vaccines for Cancer. Yale School of Medicine, 24 fev. 2026. Acesso em: 28 june. 2026.

Yale researchers have developed a machine learning model, called Immunostruct, that can help scientists create more personalized vaccines, including vaccines for cancer. They described the tool in Nature Machine Intelligence along with findings from applying it to cancer and immunology data.

    When a potential threat, such as a virus or tumor, arises in our body, our immune cells recognize peptides---essentially short proteins---on the surface of the invader and mount a defensive response. This small region that the immune system interacts with is known as an epitope. 

    Epitope-based vaccines are an emerging technology that contain specific peptides in order to trigger immune responses that precisely target particular diseases. Ongoing studies show that these vaccines are a promising potential immunotherapy for a range of cancers including melanomas, breast cancers, and glioblastomas. Researchers are also investigating whether these vaccines could more effectively combat new variants of infectious diseases.

    To develop these vaccines, scientists can use models that help them predict which peptides are most likely to trigger a strong immune response to a particular antigen. A limitation of many of these models, the researchers say, is that they treat peptides as a one-dimensional sequence of amino acids, not the three-dimensional, active structures that they are.

    Now, Yale researchers have created a model that also incorporates structural and biochemical properties of peptides. In the new study, they show that the multimodal model is more effective at identifying peptide candidates than its predecessors.

    "Cancer is extremely heterogeneous---which often makes it very hard to treat effectively," says Kevin B. Givechian, PhD, an MD-PhD student at Yale and co-first author on the study. “We have built a deep-learning model that integrates more information than had previously been combined to help us improve the identification of vaccine targets that stimulate people's immune system against their own tumor. Doing so would enable a more effective and less toxic method of treatment."

ВACKMAN, Isabella. Using Machine Learning to Develop Personalized Vaccines for Cancer. Yale School of Medicine, 24 fev. 2026. Acesso em: 28 june. 2026.